Wed, Jul 23, 2014, 12:54 AM EDT - U.S. Markets open in 8 hrs 36 mins


% | $
Click the to save as a favorite.

Transgenomic Inc. Message Board

eliapostchild 2 posts  |  Last Activity: May 19, 2014 12:24 PM Member since: Jan 26, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    from: Six Exciting Biotech Stocks

    by eliapostchild May 19, 2014 12:10 PM
    eliapostchild eliapostchild May 19, 2014 12:24 PM Flag

    google "Six Exciting Biotech Stocks" to read the rest of the conversation about Opexa.

  • eliapostchild by eliapostchild May 19, 2014 12:10 PM Flag

    CJ: Let’s start with Opexa Therapeutics Inc. (OPXA:NASDAQ). This is a very interesting company that is pursuing a novel personalized T-cell approach for a specific type of multiple sclerosis (MS) called secondary progressive MS (SPMS).

    There are about 500,000–550,000 (500–550K) patients in North America with MS, and about 85% of those patients are initially diagnosed with relapsing-remitting MS (RRMS). About 50% of those patients progress to SPMS. Opexa’s lead candidate is a therapeutic vaccine approach. We are all familiar with a virus being attenuated and injected back into a patient to mount a tailored and specific immune response. Opexa’s lead drug candidate, Tcelna (imilecleucel-T), is created using attenuated T cells, not viruses, harvested from a MS patient’s own blood. The cells are expanded ex vivo and irradiated to keep them from proliferating, and they are reintroduced via a subcutaneous injection to trigger a therapeutic immune response. The proposed schedule is to treat patients with a new five-dose series of Tcelna each year, based on the patient’s evolving immune profile. The idea is to lessen the activity of specific myelin-reactive T cells that attack the myelin sheath. Tcelna is now in a Phase 2b trial called Abili-T. The primary endpoint is reduction in whole brain atrophy.

    TLSR: The market seems to hate this company, and I’m not sure I understand why. You model a peak sales potential for the MS class of $18 billion ($18B) globally by 2019. There are 213K SPMS patients in the U.S. alone, and the company has a $42 million ($42M) market cap. Some of the companies in your coverage have doubled, tripled and quadrupled over the past 52 weeks, but Opexa is down 8% during that same period. Its relative strength is very weak.

    CJ: I see what you’re getting at, but I wouldn’t say the market hates this company. I would point out two factors that may have affected the valuation. Prior to our initiation of coverage in March, there were no other analysts

3.5999-0.1201(-3.23%)Jul 22 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.